Clinical Trials at COI Américas
During the past decade, COI Américas conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "COI Américas"
#1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at COI Américas
According to Clinical.Site data, the most researched conditions in "COI Américas" are
"Lung Cancer" (1 trials) and "Lung Neoplasms" (1 trials). Many other conditions were trialed in "COI Américas" in a lesser frequency.
Clinical Trials Intervention Types at COI Américas
Most popular intervention types in "COI Américas" are "Drug" (1 trials). Other intervention types were less common.
The name of intervention was led by "Durvalumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at COI Américas
The vast majority of trials in "COI Américas" are
2 trials for "All" genders.
Clinical Trials Status at COI Américas
Currently, there are NaN active trials in "COI Américas".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in COI Américas,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in COI Américas, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".